An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
复制标题
DOI：
10.1002/cncr.26730
复制
发表时间：
2012-09
期刊：
影响因子：
6.2
通讯作者：
P. K. Morrow;R. Murthy;J. Ensor;G. Gordon;K. Margolin;A. Elias;W. Urba;D. Weng;H. Rugo;G. Hortobagyi
中科院分区：
文献类型：
--
作者：
P. K. Morrow;R. Murthy;J. Ensor;G. Gordon;K. Margolin;A. Elias;W. Urba;D. Weng;H. Rugo;G. Hortobagyi
血管内皮生长因子 (VEGF) 的血清和血浆水平与转移性乳腺癌 (MBC) 患者的预后相关。 VEGF 与内皮细胞上的 2 个受体 VEGFR-1 和 VEGFR-2 结合。 RPI.4610 (Angiozyme0) 是一种针对 VEGFR-1 mRNA 的抗血管生成核酶。临床前和 1 期研究表明，RPI.4610 是一种耐受性良好的药物，在实体瘤中具有临床活性。作者的试验评估了 RPI.4610 治疗进展性 MBC 患者的疗效。
Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with metastatic breast cancer (MBC). VEGF binds to 2 receptors on endothelial cells, VEGFR‐1 and VEGFR‐2. RPI.4610 (Angiozyme0) is an antiangiogenic ribozyme targeting the VEGFR‐1 mRNA. Preclinical and phase 1 studies suggested that RPI.4610 is a well‐tolerated agent with clinical activity in solid tumors. The authors' trial evaluated the efficacy of RPI.4610 in the treatment of patients with progressive MBC.